Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core evidence, 2009 - Taylor & Francis
Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
[PDF][PDF] Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour - 2009 - pdfs.semanticscholar.org
Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core Evidence, 2009 - mdanderson.elsevierpure.com
Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core evidence, 2010 - pubmed.ncbi.nlm.nih.gov
Introduction Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.
E Jabbour, J Cortes, H Kantarjian - Core Evidence, 2010 - europepmc.org
Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
[PDF][PDF] Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour - 2009 - scholar.archive.org
Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
[HTML][HTML] Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core evidence, 2009 - ncbi.nlm.nih.gov
Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core Evidence, 2009 - dovepress.com
Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
review: Preclinical and clinical investigations demonstrate that nilotinib effectively …
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core Evidence, 2009 - augusta.elsevierpure.com
Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E Jabbour, J Cortes, H Kantarjian - Core Evidence, 2009 - search.proquest.com
Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …